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Introduction
Fungal infections, especially those whose incidence 
increases over time in ICU (Intensive Care Unit), 
have high mortality and morbidity. With a prolonged 
stay in ICU increase the cost of intensive care. In 
fungal infections, the limited sensitivity of diag-
nostic tests and the unresponsiveness of laboratory 
results hinder early diagnosis. Delayed and ineffective 
 treatment is one of the major causes of mortality. 
Therefore, prompt diagnosis and treatment are impera-
tive (Zaoutis et al. 2005; Armstrong-James 2007; Has-
san et al. 2009). Previous studies have demonstrated 
a higher incidence of candidemia in the post-COVID-19 
(Corona Virus Disease-19) period compared with 
the pre-COVID-19 period (Mastrangelo et al. 2020; 
Nucci et al. 2021).
Mortality due to fungal infections in ICU has been 
reported in a wide range of 5–70% (Gudlaugsson 
et al. 2003; Falagas et al. 2006). When we look at the 
international prevalence researches, it can be noticed 
that intensive care mortality increased twice in bacte-
rial infection and approximately four times in fungal 
infections. In addition, in patients diagnosed with 
COVID-19, the mortality rate associated with candi-
demia is higher in ICUs (White et al. 2019; Mastrangelo 
et al. 2020; Al-Hatmi et al. 2021).
High APACHE II score, diabetes mellitus (DM), 
neutropenia, renal failure, abdominal surgery, use of 
broad-spectrum antibiotics, total parenteral nutri-
tion, hemodialysis, mechanical ventilation, presence 
of a central venous catheter, and immunosuppressive 
treatments are important for the development of fungal 
infection in intensive care patients and are the risk fac-
tors that we frequently encounter (Pappas et al. 2016).
The aim of the present study was to evaluate fungal 
infections in intensive care patients after COVID-19 
infection and to determine mortality and risk rates.
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A b s t r a c t
Opportunistic fungal infections increase morbidity and mortality in COVID-19 patients monitored in intensive care units (ICU). As 
patients’ hospitalization days in the ICU and intubation period increase, opportunistic infections also increase, which prolongs hospital stay 
days and elevates costs. The study aimed to describe the profile of fungal infections and identify the risk factors associated with mortality 
in COVID-19 intensive care patients. The records of 627 patients hospitalized in ICU with the diagnosis of COVID-19 were investigated 
from electronic health records and hospitalization files. The demographic characteristics (age, gender), the number of ICU hospitalization 
days and mortality rates, APACHE II scores, accompanying diseases, antibiotic-steroid treatments taken during hospitalization, and micro-
biological results (blood, urine, tracheal aspirate samples) of the patients were recorded. Opportunistic fungal infection was detected in 
32 patients (5.10%) of 627 patients monitored in ICU with a COVID-19 diagnosis. The average APACHE II score of the patients was 28 ± 6. 
While 25 of the patients (78.12%) died, seven (21.87%) were discharged from the ICU. Candida parapsilosis (43.7%) was the opportunistic 
fungal agent isolated from most blood samples taken from COVID-19 positive patients. The mortality rate of COVID-19 positive patients 
with candidemia was 80%. While two out of the three patients (66.6%) for whom fungi were grown from their tracheal aspirate died, one 
patient (33.3%) was transferred to the ward. Opportunistic fungal infections increase the mortality rate of COVID-19-positive patients. 
In addition to the risk factors that we cannot change, invasive procedures should be avoided, constant blood sugar regulation should be 
applied, and unnecessary antibiotics use should be avoided.
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Experimental
Materials and Methods
The records of 627 patients hospitalized in our hos-
pital’s intensive care unit (ICU), Antalya Kepez State 
Hospital/Turkey, with COVID-19 diagnosis between 
13/03/2020 and 01/02/2021 were investigated from 
electronic health archives and hospitalization files. The 
diagnosis of COVID-19 was made by PCR (Polymer-
ase Chain Reaction) test. Culture samples were taken 
from patients who were followed up in the ICU with the 
diagnosis of COVID-19 and had a high fever and clinic 
infections. Patients over the age of 18 were included 
in our study. Neutropenic patients using immunosup-
pressive drugs and receiving chemotherapy within one 
month were not included. The samples were sent to 
the central microbiology laboratory of our hospital. 
Patients with more than 48 hours between hospitaliza-
tion date and positive blood culture were classified as 
those with hospital-acquired candidemia. Identification 
of fungal species was done with the VITEK 2 Compact 
System (Biomerieux, France) automated identification 
system. The definition of hospital infections was made 
according to the surveillance diagnosis criteria deter-
mined by the Centers for Diseases Control and Preven-
tion (CDC) (Horan et al. 2008).
Patients were classified as being colonized when 
they had no clinical symptoms of infection, but the 
fungi were isolated from their clinical specimens. The 
study did not include the colonized patients or those 
whose samples demonstrated fungal growth in less than 
48 hours. According to the CDC criteria, patients evalu-
ated by an infectious diseases specialist and considered 
infected were included in the study.
In order to determine the possible risk factors in 
terms of the demographic characteristics (age, gender) 
of the patients as well as the infection development, the 
following data were recorded: the number of days of 
ICU hospitalization and mortality rates, Acute Physio-
logy And Chronic Health Evaluation II (APACHE II) 
score, other diseases, antibiotics used within 30 days 
before Candida species isolation and the microbiolo-
gical results (blood, urine, tracheal aspirate samples).
The Ethics Committee of Health Sciences University, 
Antalya Education and Research Hospital on 01/04/2021 
approved this study under decision number 4/30.
All statistical analyzes were performed using IBM 
SPSS version 25.0 (SPSS Inc., Chicago, Illinois, USA). 
The tables present continuous variables as the mean 
± SD, while categorical variables are presented as num-
ber (N) and percentage (%). Comparisons between 
groups were made using the Mann-Whitney U test for 
continuous variables and using Fisher’s exact test for 
categorical variables. P-value (p < 0.05) was considered 
statistically significant (Rotondo et al. 2020).
Results
Fungal infection was detected in 32/627 patients 
(5.1%) who were followed up in ICU with a diagnosis 
of COVID-19. Twenty-eight patients were SARS-CoV-2 
PCR positive, and four were considered positive with 
clinical and lung tomography findings. The average 
age of the patients was 73.5. The average APACHE II 
score of the patients was 28 ± 6. While 25 of the patients 
(78.12%) died, seven patients (21.87%) were discharged 
from the ICU. The demographic variables of the patients 
are presented in Table I.
Gender
  Female   8 25.0
  Male  24 75.0
Age (year)  73.50 (52–94) 73.43 ± 10.14
  50–59   4 12.5
  60–79  16 50.0
  ≥ 80 12 37.5
BMI* (kg/m2)
  Female 28.89 (20.41–44.44) 
  Male 27.68 (20.76–44.98) 
Smoking status
  Female  2 25.0
  Male 14  58.33
Table I
Descriptive variables related to patients.






or Mean ± SD
A total of 57 separate fungal infection cases were 
detected in 32 COVID-19 patients treated in ICU. 
Totally 16 Candida sp. isolates were grown from blood 
samples, candidemia was confirmed, and antifungal 
treatment was started. Candida sp. growth in the urine 
samples was evaluated as candiduria. All patients had 
urinary catheterization. The culture of urine samples 
was repeated 24 hours after urinary catheter replace-
ment in these patients. Since no urological surgical 
intervention was planned in any patient, patients with 
isolated candiduria were not treated. The presence of 
Candida sp. in urine was considered as colonization 
in these patients. Mechanical ventilator-induced colo-
nization of Candida sp. was observed as their growth 
from tracheal aspirates and was very common as a poor 
predictor for the diagnosis of pneumonia. Candida sp. 
isolation from the aspirate cultures was not considered 
pneumonia and was treated as colonization. The pres-
ence of three Aspergillus sp. strains, obtained from the 
aspirate samples, was also considered the colonization 
because the radiological imaging and clinical findings 
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The accompanying comorbidities of the patients 
from whom the fungi were isolated from clinical speci-
mens are given in Table IV. The most common cardio-
vascular disease (68%) and diabetes mellitus (34.4%) 
were detected.
The risk factors of cases with fungal infection are 
shown in Table V. Central venous catheter was used in 
all patients who developed candidemia.
Candida parapsilosis was the opportunistic fungal 
agent that was isolated from the most (43.7%) blood 
cultures of COVID-19 patients; Candida tropicalis 
(33.33%) was the most commonly isolated from tra-
cheal aspirates, and Candida albicans (48.27%) was the 
most common in urine cultures (Table VI).
All patients were given carbapenem and glyco-
peptide simultaneously during the last month before 
fungal infection, and this period was even extended 
up to 30 days. Except for five patients, in the remaining 
27 patients, carbapenem was combined with an anti-
biotic of the oxazolidinone group or glycopeptide type 
(Table VII).
Of the 15 patients with candidemia, 12 died (two 
fungal infection cases were detected in one patient), and 
Blood 16 23.2
Aspirate 12 17.4
Urine  29 42.1
Urine + blood 8 11.6
Aspirate + blood 3 4.4
Aspirate + urine 1 1.3
Table II
Isolation of fungi from the clinical specimens.
* – Since the categories were multiple-response,






1–30days  4 25
> 30 days 12 75
Table III





Diabetes mellitus 11 (34.4)
Cardiovascular disease* 22 (68.8)
Respiratory disease  6 (18.8)
Neurological disease 11 (34.4)
Renal disease  1 (3.1)
Table IV
Distribution of fungal infection cases based on accompanying 
diseases.






did not support the infection. Isolated zones and num-
bers are presented in Table II.
The distribution of candidemia cases by the number 
of hospitalization days is given in Table III. Candidemia 
was observed far more frequently in patients hospital-
ized for longer than 30 days.
Parenteral nutrition
No 25 (78.1) 45 (78.95)
Yes  7 (21.9) 12 (21.05)
Steroid use
No 20 (62.5) 44 (77.19)
Yes 12 (37.5) 13 (22.81)
ICU insulin use
No 12 (37.5) 24 (42.11)
Yes 20 (62.5) 33 (57.89)
Central venous catheter
No 14 (43.75) 45 (78.95)
Yes 18 (56.25) 12 (21.05)
Table V





Candida tropicalis 20 (35.08) 5 (31.25) 4 (33.33) 11 (37.93)
Candida albicans 18 (31.58) 4 (25.00) 0 (0.00) 14 (48.27)
Candida parapsilosis 14 (24.56) 7 (43.75) 3 (25)  4 (13.79)
Aspergillus spp.  3 (5.28) 0 (0.00) 3 (25)  0 (0.00)
Candida lusitaniae  1 (1.75) 0 (0.00) 1 (8.34)  0 (0.00)
Trichosporon mucoides  1 (1.75) 0 (0.00) 1 (8.34)  0 (0.00)
Table VI
Distribution of fungal species in blood, tracheal aspirate, and urine cultures.







Total: 16 Total: 12 Total: 29
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the mortality rate in candidemia was found to be 80%. 
Moreover, two of the three patients (66.6%), who had 
Aspergillus sp. grown in their tracheal aspirate died, one 
patient (33.3%) was transferred to the ward.
Discussion
In our study, 16 (2.6%) of 627 patients with COVID-19 
followed in the ICU developed candidemia. Nori et al. 
(2021) found that eight (5%) of the 152 COVID-19 
patients had developed candidemia. Similarly, in our 
study, this rate was found to be 2.6%.
In our study, C. parapsilosis was the leading agent 
of candidemia (n = 7, 43%), C. tropicalis at (n = 5, 31%) 
was the second, and C. albicans (n = 4, 25%) was the 
third. Similarly, Tokak et al. (2020) ranked C. parapsilo-
sis (48.4%) the first and C. albicans (32.3%) the second 
in candidemia. Cortés et al. (2021) identified C. parapsi-
losis as the most common factor (38.5%) in their study.
In a study conducted by Segrelles-Calvo et al. 
(2021), Aspergillus sp. was detected in respiratory tract 
samples of seven (5.4%) out of 215 patients followed 
up in the ICU. The mortality rate of these patients was 
found to be 86%. Another study reported aspergillo-
sis in 19 (17.9%) out of 106 patients with COVID-19 
admitted to ICU. At the outcome of 42-day ICU admit-
tance, seven patients died (Dupont et al. 2021). In our 
study, two out of three patients (66.6%) with aspergil-
losis died, one patient (33.3%) was transferred to the 
ward. Schauwvlieghe et al. (2018) defined invasive pul-
monary aspergillosis in influenza as an independent 
risk factor associated with mortality (IPA). As in our 
study, aspergillosis was also associated with increased 
mortality for COVID-19 patients.
We found an 80% mortality rate in our patients who 
developed candidemia. It has been reported that candi-
demia mortality varies between 5–71% in ICUs (Patolia 
et al. 2013). Our high mortality rate can be explained 
by being tertiary ICU, high mean age of the patients, 
and the fact that the patients have multiple risk factors 
for candidemia.
In our study, hospitalized patients had high 
APACHE  II scores and extensive use of antibiotics. 
Morrell et al. (2005) found that antimicrobial exposure 
and high APACHE II scores were independently asso-
ciated with hospital mortality in patients with candi-
demia. The other study from Kansas City that included 
patients with diabetes mellitus and candidemia infec-
tions showed that mortality was related to the severity 
of illness, as measured by the Apache score, mechani-
cal ventilation, and clinical appearance of the infection 
(Bader et al. 2004). In their study, Cortés et al. (2021) 
stated that diabetes mellitus accompanies candidemia 
with COVID-19 in 13 patients (11.9%) and that this 
comorbidity increased mortality and was an independ-
ent risk factor for mortality.
In our study, diabetes mellitus was present in 
11  (34.4%) patients who developed fungal infection. 
Diabetes mellitus was the second most common 
comorbidity disease group in patients with COVID-19 
fungal infection. The most common comorbidity was 
cardiovascular diseases. Similarly, Kaur and Chakra-
barti (2017) also reported an increase in mortalities due 
to cardiovascular diseases, an increase in access to criti-
cal care units, and an increase in the incidence of can-
didemia in such units. This situation can be explained 
by the high mean age of the inpatients and the fact that 
the patients do not receive regular treatment.
Yang et al. (2020) emphasized the higher possibility 
of developing fungal co-infection in patients who were 
followed up in the ICU requiring mechanical ventila-
tion and hospitalization longer than 50 days. Also, in 
our study, 75% of the patients with candidemia were 
hospitalized in the ICU for more than 30  days. Pro-
longed ICU stays increase the risk of candidemia.
Due to the severe cytokine release, COVID-19 ster-
oid medication is applied. In a study investigating the 
use and effect of steroids, 226 hospitalized patients with 
COVID-19 were examined. Those who received steroid 
medication were found to have higher rates of bacte-
rial infections (25% versus 13.1%, p = 0.041) and fungal 
infections (12.7% versus 0.7%, p < 0.001) (Obata et al. 
2021). In our study, fungi were detected in 33 speci-
mens from 12 patients (275%) who received steroid 
medication, while they were isolated from 44 samples 
from 20 patients (220%) who did not receive steroid 
medication. We determined that opportunistic fungal 
infection increased with the use of steroids.
It is known that the use of broad-spectrum antibiot-
ics increases the patient’s susceptibility to candidemia. 
Antibiotics are widely used in patients with COVID-19, 
especially those receiving treatment in ICU, and these 
antibiotics are started empirically. Recent World Health 
Organization guidelines recommend empiric antibiotics 
only for patients with severe COVID-19, using host fac-
tors and local epidemiology to drive antibiotic selection 
Carbapenem 32 (100%) 17 ± 12.52
Glycopeptide 32 (100%) 13 ± 7.4
Linezolid 23 (71.87%) 10 ± 7.30
Quinolone 11 (33.3%) 14 ± 7.20
Tigecycline  8 (24.24%) 12 ± 5
Aminoglycoside  2 (6.06%) 10 ± 2.3
Table VII







Days of using 
antibiotic before
fungal infection
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(WHO 2020). Lai et al. (2020) reported that empirical 
antibiotics were prescribed for 90% of patients despite 
the low confirmation of secondary bacterial infections 
(10%). Similarly, in a study conducted by Rawson et al. 
(2020), 70% of COVID-19 patients received antimicro-
bial therapy, while only 10% had bacterial or fungal 
infections. In our ICU clinic, treatments with antibio-
tics started empirically for each patient, and during the 
treatment, combined antibiotics were used, and at least 
one of them was a broad-spectrum antibiotic. All of 
the patients used carbapenem and glycopeptide simul-
taneously during the last month before fungal infec-
tion, and this period was even extended up to 30 days. 
The rate of antibiotic use of patients in ICU was 98.7% 
during the days they were hospitalized. Such extensive 
use of antibiotics lays the groundwork for opportunis-
tic infections. This situation indicates the necessity of 
using a new algorithm of antibiotics use for COVID-19 
patients in intensive care units. One hundred sixty-six 
doctors from 23 countries and 82 different hospitals 
participated in a survey study conducted on antibiotics 
in COVID-19 patients. The study revealed the use of 
widespread broad-spectrum antibiotics in COVID-19 
patients. In COVID-19 patients hospitalized in ICU, 
piperacillin/ tazobactam were the most frequently 
prescribed antibiotics, and the mean duration of anti-
biotic treatment was found to be 7.12 (SD = 2.44) days 
(Beović et al. 2020). Similar to our study, Sarı et al. 
(2018) found higher use of carbapenem in patients who 
developed candidemia. Rawson et al. (2020) summa-
rized nine studies reporting data on co-infections in 
COVID-19 patients. A rate of 8% was found for bacte-
rial and fungal co-infections in this study. It empha-
sized that bacterial co-infections are lower in patients 
with COVID 19, and it is necessary to avoid starting 
immediate treatment with antibiotics.
The small number of patient samples limited our 
study. The strength of our study is the conclusion that 
broad-spectrum and long-term antibiotics used in 
intensive care patients with a diagnosis of COVID-19 
are a significant risk factor for fungal growth.
Conclusions
In patients with COVID-19, cell-mediated immu-
nosuppression, widespread use of antibiotics, a steroid 
medication, and impaired glucose tolerance laid the 
foundations for opportunistic infections. Co-infec-
tions, especially fungal infections, increase the num-
ber of days and mortality of ICU patients. Given the 
high mortality, early recognition of candidemia and the 
need for appropriate antifungal therapy are key require-
ments to improve outcomes for COVID-19 patients in 
the ICU. In addition to the risk factors that we cannot 
change, invasive procedures should be avoided, fre-
quent blood sugar regulation should be applied, and 
unnecessary or inappropriate antibiotics use should be 
avoided. The antibiotic use guidelines should be estab-
lished for COVID-19 patients.
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